InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

InnoCare Pharma (HKEX: 09969; SSE: 688428) has announced that the first psoriasis patient has been dosed in a clinical trial of their TYK2 allosteric inhibitor ICP-488 in China. The phase I clinical trial has already completed single ascending doses (SAD) and multiple ascending doses (MAD) of ICP-488, showing a well-tolerated safety profile. The ongoing study aims to evaluate the safety and effi..

• format_list_bulleted Pharmacology/BS
• · 2023. 7. 6.
• textsms

2seventy bio's CAR-T Trial Halted After Pediatric Death

2seventy bio has paused its Phase I CAR T-cell therapy trial for pediatric acute myeloid leukemia after a patient death. The trial was being conducted in partnership with Seattle Children’s, and the company's DARIC technology is used to regulate CAR T-cell responses and enable "on-demand" control of engineered T-cells. The child who died was the first to receive the second dose level of 2seventy..

• format_list_bulleted Pharmacology/BS
• · 2023. 6. 15.
• textsms